Matthew B. Harms, MD, on the Necessity of Tracking Gene Mutations in ALS
The associate professor of neurology at Columbia University spoke about the importance of identifying patients with ALS-associated gene mutations as early as possible.
Matthew B. Harms, MD, on Gene Therapy’s Potential to Address Unmet Needs in ALS
The associate professor of neurology at Columbia University spoke about the current and future treatment landscape in ALS.
Matthew B. Harms, MD, on Gene Therapy in ALS, MDA 2023
The associate professor of neurology at Columbia University spoke about the session he will be chairing at MDA’s 2023 conference.